Cargando…
Molecular Signatures in Urologic Tumors
Urologic tumors continue to represent a huge fraction of cancer cases in the United States, with over 376,310 estimated new diagnoses in 2013. As with many types of tumors, urologic tumors vary greatly in their phenotype, ranging from minimally invasive to malignancies possessing great metastatic po...
Autores principales: | Larkin, Spencer, Kyprianou, Natasha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794787/ https://www.ncbi.nlm.nih.gov/pubmed/24018887 http://dx.doi.org/10.3390/ijms140918421 |
Ejemplares similares
-
The Promise of Novel Molecular Markers in Bladder Cancer
por: Miremami, Jahan, et al.
Publicado: (2014) -
Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable
por: Katims, Andrew B., et al.
Publicado: (2020) -
Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression
por: Grant, Campbell M., et al.
Publicado: (2013) -
Prostate tumor neuroendocrine differentiation via EMT: The road less traveled
por: Dicken, Haley, et al.
Publicado: (2019) -
3D Tumor Models in Urology
por: Neuhaus, Jochen, et al.
Publicado: (2023)